These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10146999)

  • 1. A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries.
    Leese B; Hutton J; Maynard A
    Pharmacoeconomics; 1992 May; 1(5):346-56. PubMed ID: 10146999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.
    Whittington R; Barradell LB; Benfield P
    Pharmacoeconomics; 1993 Jan; 3(1):45-82. PubMed ID: 10146987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probabilistic cost-minimisation analysis of darbepoetin alpha versus epoetin alpha in treating anaemia secondary to chronic renal failure. Assessment in Spanish clinical practice.
    Sanz-Granda A
    Farm Hosp; 2009; 33(4):208-16. PubMed ID: 19712609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
    Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B
    Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.
    Collins AJ
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 2():ii2-6. PubMed ID: 12819293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human erythropoietin: factors to consider in cost-benefit analysis.
    Sheingold SH; Churchill DN; Muirhead N; Laupacis A
    Am J Kidney Dis; 1991 Jan; 17(1):86-92. PubMed ID: 1898836
    [No Abstract]   [Full Text] [Related]  

  • 9. Benefits and costs of recombinant human erythropoietin for end-stage renal failure: a review. Benefits and costs of erythropoietin.
    McNamee P; van Doorslaer E; Segaar R
    Int J Technol Assess Health Care; 1993; 9(4):490-504. PubMed ID: 8288425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia.
    Cremieux PY; Finkelstein SN; Berndt ER; Crawford J; Slavin MB
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):459-72. PubMed ID: 10662393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dosage epoetin in maintenance haemodialysis: costs and quality-of-life improvement.
    Harris DC
    Pharmacoeconomics; 1994 Jan; 5(1):18-28. PubMed ID: 10146863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.
    Dunn CJ; Wagstaff AJ
    Drugs Aging; 1995 Aug; 7(2):131-56. PubMed ID: 7579784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure.
    Dunn CJ; Markham A
    Drugs; 1996 Feb; 51(2):299-318. PubMed ID: 8808169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epoetin: human recombinant erythropoietin.
    Flaharty KK; Grimm AM; Vlasses PH
    Clin Pharm; 1989 Nov; 8(11):769-82. PubMed ID: 2680241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of epoetin and autologous blood donationin reducing allogeneic blood transfusions incoronary artery bypass graft surgery.
    Marchetti M; Barosi G
    Transfusion; 2000 Jun; 40(6):673-81. PubMed ID: 10864987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
    Thanakitcharu P; Siriwiwatanakul N
    J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of epoetin in chronic renal failure.
    Coyne DW
    JAMA; 2007 Apr; 297(15):1713-6. PubMed ID: 17440149
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
    Moran LJ; Carey P; Johnson CA
    Am J Hosp Pharm; 1992 Jun; 49(6):1451-4. PubMed ID: 1529988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
    Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
    Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.